500 experts at the 7th AMR Conference in Basel
How to stop hard-to-diagnose, treatment-resistant microbial pathogens was discussed by experts from 13 countries at the 7th AMR Conference in Basel.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
Vitestro raises 12m in Series A financing
/in News/by Thomas GabrielczykWith assets of 12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market.
European VCs join US$105m financing of US Mediar Thx
/in News/by Thomas GabrielczykMediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund […]
Iktos SA raises 15.5m in Series A financing
/in News/by Thomas GabrielczykParis-based AI-inspired drug discovery specialist Iktos SA has closed a 15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.
Oculis lists at Nasdaq through SPAC merger
/in News/by Thomas GabrielczykThe eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.
Confo Therapeutics and Lilly partner to advance CFTX-1554
/in News/by Thomas GabrielczykDrug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.
German HTGF IV fund closes at 493m
/in News/by Thomas GabrielczykThe fourth fund of High-Tech Gründerfonds has reached a final fund volume of 493.8m
5 Alarm Bio Ltd raises £500K in seed round
/in News/by Thomas GabrielczykBritish anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.
High blood pressure reprograms immune system
/in News/by Thomas GabrielczykInterferon-gamma overexpression leads to hypertension-induced damage to the blood-brain barrier by reprogrammed macrophages.
Abivax SA raises 130m to advance obefazimod to Phase III
/in News/by Thomas GabrielczykFrench Abivax SA has raised 130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow.